首页> 外文期刊>Journal of Perinatal Medicine >11 beta-hydroxysteroid dehydrogenase (11 beta-HSD-II) activity in human placenta: its relationship to placental weight and birth weight and its possible role in hypertension.
【24h】

11 beta-hydroxysteroid dehydrogenase (11 beta-HSD-II) activity in human placenta: its relationship to placental weight and birth weight and its possible role in hypertension.

机译:人类胎盘中的11β-羟类固醇脱氢酶(11β-HSD-II)活性:与胎盘重量和出生体重的关系及其在高血压中的可能作用。

获取原文
获取原文并翻译 | 示例
           

摘要

It has been assumed that low birth weight and high placenta weight were key factors for predicting hypertension in human adulthood. A deficiency in placental 11 beta-HSD-II enzyme activity was supposed to be the underlying cause. To possibly establish 11 beta-HSD-II as a leading factor, we determined 11 beta-HSD-II activities in 133 healthy pregnancies, 21 proteinuric pregnancies complicated by pregnancy-induced hypertension (PIH), 26 non proteinuric PIH pregnancies and 15 pregnancies complicated by fetal growth restriction (32nd-41st gestational week). We could not identify differences in 11 beta-HSD-II activity between pregnancies with the rare combination of small babies with big placentas and others (p = 0.59; Kruskal-Wallis test). And although there was no correlation between 11 beta-HSD-II activity and birth weight, in the control gestational age correlated with 11 beta-HSD-II activity (r = 0.22; p < 0.05; Spearman). 11 beta-HSD-II activity in the proteinuric PIH group was significantly higher than in the controls (11.7 pmol/min/mg prot.; range 10-13.2 vs. 7.9; range 7.0-9.1; p < 0.05). The lowest, but not significant, enzyme activities were in the IUGR group (5.8 pmol/min/mg prot.; range 4.0-9.2). In this group, analysis of variance detected a correlation between enzyme activity and placental weight. In conclusion, we could not confirm that placental 11 beta-HSD-II deficiencies act as an indicator for the risk of adult hypertension in small fetuses with large placentas. However, in growth restriction 11 beta-HSD-II activity might play a role. To clarify the influence in this group, further research is needed. Increased 11 beta-HSD-II activities with gestational age in the control may serve to sustain fetal adrenal steroid genesis and to prepare the fetus for autonomic life.
机译:假定低出生体重和高胎盘体重是预测成年高血压的关键因素。胎盘11β-HSD-II酶活性不足被认为是其根本原因。为了确定11个β-HSD-II为主导因素,我们确定了133例健康妊娠,21例蛋白尿合并并发妊娠高血压病(PIH),26例非蛋白尿PIH妊娠和15例复杂妊娠的11种β-HSD-II活性。受胎儿生长限制(胎龄第32-41周)。我们无法确定孕妇与稀有大胎盘婴儿和其他婴儿的罕见组合在11β-HSD-II活性之间的差异(p = 0.59; Kruskal-Wallis检验)。尽管11β-HSD-II活性与出生体重之间无相关性,但在对照胎龄中,11β-HSD-II活性相关(r = 0.22; p <0.05; Spearman)。蛋白尿PIH组的11β-HSD-II活性显着高于对照组(11.7 pmol / min / mg蛋白;范围10-13.2与7.9;范围7.0-9.1; p <0.05)。 IUGR组的酶活性最低,但不显着(5.8 pmol / min / mg蛋白质;范围4.0-9.2)。在该组中,方差分析检测到酶活性与胎盘重量之间的相关性。总之,我们无法确定胎盘11β-HSD-II缺陷可作为具有大量胎盘的小胎儿成年高血压风险的指标。但是,在生长受限11中,β-HSD-II活性可能起作用。为了弄清这一群体的影响,需要进一步的研究。在对照组中,随着胎龄的增加,β-HSD-II活性增加了11个,可能有助于维持胎儿肾上腺类固醇的发生,并使胎儿为自主生命做好准备。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号